Oncology LSX2026: Addressing adult eye cancer, with Roi Raz Roi Raz, CEO of ReBio Pharma, discusses injectable, bioresorbable sustained release delivery for ophthalmic therapeutics at LSX 2026.
R&D Partner Content 5th Gene Therapy for Ophthalmic Disorders Summit Ophthalmic drug developers are unlocking the full potential of gene therapy.
Partner Content Partner Content Exclusive interview with ForwardVue Pharma released for Opht... Exclusive interview with ForwardVue Pharma
Partner Content Partner Content Ophthalmic Drug Delivery Development - Trials and Tribulatio... Ophthalmic Drug Delivery Development Workshop
Partner Content Partner Content Novel Platforms in Ocular Drug Delivery workshop discussed a... Novel Platforms in Ocular Drug Delivery workshop
Partner Content Partner Content Aerie Pharmaceuticals interview released for Ophthalmic Drug... Ophthalmic Drugs
News FDA clears Viridian's Tepezza rival for thyroid eye disease Viridian has fired a shot across Amgen's bows with the FDA approval of Tepezza rival Lumvoa in thyroid eye disease, a $2bn market.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.